Document is current
Any future updates will be listed below
-
Authors
Buhl, Timo https://orcid.org/0000-0002-3139-129X
Bauer, Andrea
Ehst, Benjamin D.
Thyssen, Jacob P.
Hahn-Pedersen, Julie
Hagen, Berith Fredsted
Apol, Eydna D.
Agner, Tove
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03683719 at ClinicalTrials.govDocuments that mention this clinical trial
Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream
https://doi.org/10.1007/s13555-025-01384-4
Development and Validation of a Patient-Reported Outcome Measure of the Impact of Chronic Hand Eczema on Health-Related Quality of Life: the Hand Eczema Impact Scale (HEIS)
https://doi.org/10.1007/s13555-024-01267-0
Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD)
https://doi.org/10.1007/s13555-024-01114-2
-
Funding
Funding for this research was provided by:
LEO Pharma
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 6 March 2025
First Online: 5 April 2025
Declarations
:
: Timo Buhl has been a speaker/investigator/advisor for AbbVie, ALK, Almirall, AstraZeneca, Bencard, Eli Lilly, Incyte, Galderma, Janssen, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, R-Biopharm, Sanofi and ThermoFisher. Andrea Bauer has been a speaker/advisor/investigator and/or received research funding from AbbVie, Almirall, Amgen, AstraZeneca, Biofrontera, Bristol-Myers Squibb, Celldex, Eli Lilly, Escient, Galderma, Genentech, Gilead, Incyte, Janssen, Jasper, LEO Pharma, L’Oréal, Novartis, Pfizer, Pharvaris, Sanofi/Regeneron and Shire/Takeda. Benjamin D. Ehst has been a speaker/advisor/investigator and/or received research funding from AbbVie, Acelyrin, Aclaris, Allakos, Almirall, Alumis, Amgen, AnaptysBio, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert Pharma, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, Kymab, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma and Ventyx. Julie Hahn-Pedersen was an employee of LEO Pharma A/S, Ballerup, Denmark at the time of the study and is currently employed by Novo Nordisk A/S. Berith Fredsted Hagen was an employee of LEO Pharma A/S, Ballerup, Denmark at the time of the study and is currently employed by Zealand Pharma. Jacob P. Thyssen was an employee at the Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Denmark at the time of the study and is currently employed at LEO Pharma A/S, Ballerup, Denmark. Eydna D. Apol is an employee at LEO Pharma A/S, Ballerup, Denmark. Tove Agner has been a speaker/investigator/advisor for AbbVie, Almirall, Eli Lilly, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme.
: The trial was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, Good Clinical Practice guidelines, and applicable regulatory requirements, and was approved by the Regional Committees on Health Research Ethics for Capital Region of Denmark (reference number 18047858), and independent ethics committees or institutional review boards for each study site (supplementary material). All patients provided written informed consent.
